A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

Randomised, triple-masked, parallel-group Phase III study comparing a single oral 100 µg dose of MM120 (LSD D‑tartrate) to placebo in adults with moderate to severe MDD; primary double-blind period is 12 weeks with a 40‑week open‑label extension.

Approximately 140 participants aged 18–74 with MADRS ≥26 and CGI‑S ≥4 will be enrolled; safety monitoring and pre-specified criteria determine eligibility for open‑label extension.